Non-Animal Testing Models Crucial for India's Next Phase of Pharmaceutical Growth
Non-animal testing models (NAMs) are becoming crucial for the next phase of pharmaceutical growth, especially for India's transition from generic manufacturing to original drug discovery. Currently, only 10-14% of drug candidates entering clinical trials receive regulatory approval, partly due to animal testing's poor predictive accuracy for human body behavior. NAMs, including organoids, organ-on-chip platforms, and AI-enabled computational models, offer human biology-grounded insights, improving predictive accuracy and shortening development timelines. India needs a national framework and clear regulations to integrate NAMs effectively, leveraging its strengths in generics and biosimilars to become a hub for drug discovery and innovation.
Key Points
- Non-animal testing models (NAMs) are essential for improving drug discovery and reducing reliance on animal testing.
- Animal testing often has poor predictive accuracy, contributing to high failure rates in drug development.
- NAMs like organoids and AI-enabled models offer more human-relevant insights, improving accuracy and speeding up timelines.
- India needs a national framework and clear regulations to integrate NAMs and transition to original drug discovery.
Exam Facts
- Drug candidate approval rate: 10-14% (after Phase I clinical trials)
- NAMs examples: organoids, organ-on-chip platforms, computational models, AI-enabled approaches
- Countries with NAMs frameworks: U.S., European Union, U.K., Japan
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.